Natera, Inc. $NTRA Shares Purchased by Wedmont Private Capital

Wedmont Private Capital raised its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 4.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,580 shares of the medical research company’s stock after purchasing an additional 74 shares during the period. Wedmont Private Capital’s holdings in Natera were worth $256,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of NTRA. Quantinno Capital Management LP acquired a new position in Natera during the fourth quarter worth approximately $373,000. Focus Partners Advisor Solutions LLC acquired a new stake in shares of Natera in the fourth quarter worth $227,000. Forum Financial Management LP acquired a new stake in shares of Natera in the fourth quarter worth $327,000. Mackenzie Financial Corp increased its position in shares of Natera by 33.9% in the fourth quarter. Mackenzie Financial Corp now owns 4,317 shares of the medical research company’s stock worth $683,000 after acquiring an additional 1,092 shares in the last quarter. Finally, Polar Asset Management Partners Inc. increased its position in shares of Natera by 1.6% in the fourth quarter. Polar Asset Management Partners Inc. now owns 96,105 shares of the medical research company’s stock worth $15,213,000 after acquiring an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on NTRA shares. Barclays reissued an “overweight” rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Cowen reissued a “buy” rating on shares of Natera in a research report on Friday, August 8th. Stephens reissued an “overweight” rating and issued a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. Piper Sandler restated an “overweight” rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Finally, Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 target price for the company in a research note on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $194.00.

Natera Stock Performance

Natera stock opened at $181.11 on Monday. The firm’s 50-day moving average is $156.80 and its 200-day moving average is $155.19. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $183.00. The company has a market cap of $24.86 billion, a P/E ratio of -94.82 and a beta of 1.68.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same period last year, the business earned ($0.30) EPS. The firm’s revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider John Fesko sold 678 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $105,401.88. Following the sale, the insider owned 152,747 shares of the company’s stock, valued at $23,746,048.62. This trade represents a 0.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 5,079 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $166.53, for a total transaction of $845,805.87. Following the transaction, the chief executive officer directly owned 158,514 shares in the company, valued at approximately $26,397,336.42. The trade was a 3.10% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,423 shares of company stock worth $8,459,656. 5.63% of the stock is owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.